PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21175263-16 2011 CONCLUSIONS: This study demonstrates that c-Src, ERK, and AKT played a protective role during TAM-induced apoptosis, and that c-Cbl sensitized MCF-7 cells to TAM by modulating the expression of c-Src, and TAM-induced ERK and AKT activity. Tamoxifen 158-161 Cbl proto-oncogene Homo sapiens 126-131 21175263-16 2011 CONCLUSIONS: This study demonstrates that c-Src, ERK, and AKT played a protective role during TAM-induced apoptosis, and that c-Cbl sensitized MCF-7 cells to TAM by modulating the expression of c-Src, and TAM-induced ERK and AKT activity. Tamoxifen 158-161 Cbl proto-oncogene Homo sapiens 126-131 21175263-0 2011 Ubiquitin ligase c-Cbl is involved in tamoxifen-induced apoptosis of MCF-7 cells by downregulating the survival signals. Tamoxifen 38-47 Cbl proto-oncogene Homo sapiens 17-22 21175263-13 2011 Over-expression of c-Cbl significantly enhanced the apoptosis-inducing effects of TAM, while 70Z/Cbl suppressed the apoptosis-inducing effects of TAM. Tamoxifen 82-85 Cbl proto-oncogene Homo sapiens 19-24 21175263-13 2011 Over-expression of c-Cbl significantly enhanced the apoptosis-inducing effects of TAM, while 70Z/Cbl suppressed the apoptosis-inducing effects of TAM. Tamoxifen 82-85 Cbl proto-oncogene Homo sapiens 21-24 21175263-14 2011 Further investigation revealed that, overexpression of c-Cbl significantly downregulated the c-Src protein levels and TAM-induced AKT activity. Tamoxifen 118-121 Cbl proto-oncogene Homo sapiens 55-60 21175263-15 2011 But 70Z/Cbl significantly upregulated TAM-induced ERK and AKT activity. Tamoxifen 38-41 Cbl proto-oncogene Homo sapiens 8-11 29720121-0 2018 C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells. Tamoxifen 29-38 Cbl proto-oncogene Homo sapiens 0-5 29720121-15 2018 In addition, c-Cbl could reverse tamoxifen resistance in BT474 cells, but the ubiquitin ligase mutant had no effect. Tamoxifen 33-42 Cbl proto-oncogene Homo sapiens 13-18 29720121-18 2018 CONCLUSIONS: Our results suggested that c-Cbl can reverse tamoxifen resistance in HER2-overexpressing breast cancer cells by inhibiting the formation of the ER-c-Src-HER2 complex. Tamoxifen 58-67 Cbl proto-oncogene Homo sapiens 40-45 28100467-4 2017 Using a newly engineered tamoxifen-inducible Cbl and Cbl-b deletion model with a dual fluorescent reporter (Cblflox/flox; Cbl-bflox/flox; Rosa26-CreERT; mT/mG), we show that Cbl/Cbl-b DKO in mammary organoids leads to hyperactivation of AKT-mTOR signaling with depletion of MaSCs. Tamoxifen 25-34 Cbl proto-oncogene Homo sapiens 45-48 25481740-6 2015 Restoration of normal c-Cbl function also allows more effective harnessing of estrogen receptor-alpha (ERalpha)-independent activities of tamoxifen to activate the RFC pathway and target ERalpha-negative cancer cells. Tamoxifen 138-147 Cbl proto-oncogene Homo sapiens 22-27 23606532-0 2013 Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. Tamoxifen 96-105 Cbl proto-oncogene Homo sapiens 24-29